U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H11F6N7O
Molecular Weight 443.3066
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SELINEXOR

SMILES

C(\[H])(=C(\[H])/n1cnc(-c2cc(cc(c2)C(F)(F)F)C(F)(F)F)n1)/C(=NN=c3cncc[nH]3)O

InChI

InChIKey=DEVSOMFAQLZNKR-RJRFIUFISA-N
InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-

HIDE SMILES / InChI
Selinexor (KPT-330) is a first in class XPO1 antagonist being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

CNS Activity

Curator's Comment:: In clinical trials, the dose-limiting side effects of selinexor are central nervous system (CNS)-mediated anorexia with weight loss and malaise, as well as thrombocytopenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
680 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5386 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SELINEXOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Other AEs: Thrombocytopenia, Thrombocytopenia...
Other AEs:
Thrombocytopenia (grade 4, 1%)
Thrombocytopenia (grade 3, 23%)
Thrombocytopenia (grade 1-2, 22%)
Hyponatremia (grade 4, 1%)
Hyponatremia (grade 3, 8%)
Hyponatremia (grade 1-2, 3%)
Nausea (grade 3, 12%)
Nausea (grade 1-2, 60%)
Fatigue (grade 3, 14%)
Fatigue (grade 1-2, 52%)
Decreased appetite (grade 3, 5%)
Decreased appetite (grade 1-2, 49%)
Vomiting (grade 3, 7%)
Vomiting (grade 1-2, 49%)
Weight loss (grade 1-2, 55%)
Anemia (grade 3, 11%)
Anemia (grade 1-2, 29%)
Dysgeusia (grade 1-2, 30%)
Blurred vision (grade 3, 1%)
Blurred vision (grade 1-2, 21%)
Diarrhea (grade 3, 1%)
Diarrhea (grade 1-2, 19%)
Constipation (grade 1-2, 8%)
Dizziness (grade 1-2, 14%)
Sources:
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Disc. AE: Diarrhea, Pyrexia...
Other AEs: Thrombocytopenia, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (grade 3, 3%)
Pyrexia (grade 3, 4%)
Other AEs:
Thrombocytopenia (grade 4, 15%)
Neutropenia (grade 4, 9%)
Anaemia (grade 4, 1%)
Fatigue (grade 3, 11%)
Hyponatraemia (grade 3, 8%)
Nausea (grade 3, 6%)
Dyspnoea (grade 4, 1%)
Acute respiratory distress syndrome (grade 5, 1 patient)
Cerebrovascular accident (grade 5, 1 patient)
Sepsis (grade 5, 3 patients)
Sources:
100 mg 2 times / week multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / week
Route: oral
Route: multiple
Dose: 100 mg, 2 times / week
Sources:
unhealthy
n = 92
Health Status: unhealthy
Population Size: 92
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 1-2, 14%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Diarrhea grade 1-2, 19%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Blurred vision grade 1-2, 21%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 1-2, 22%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Anemia grade 1-2, 29%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 1-2, 3%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Dysgeusia grade 1-2, 30%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Decreased appetite grade 1-2, 49%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Vomiting grade 1-2, 49%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 1-2, 52%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Weight loss grade 1-2, 55%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Nausea grade 1-2, 60%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Constipation grade 1-2, 8%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Blurred vision grade 3, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Diarrhea grade 3, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Anemia grade 3, 11%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Nausea grade 3, 12%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 3, 14%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 3, 23%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Decreased appetite grade 3, 5%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Vomiting grade 3, 7%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 3, 8%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Hyponatremia grade 4, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Thrombocytopenia grade 4, 1%
50 mg/m2 2 times / week multiple, oral
Dose: 50 mg/m2, 2 times / week
Route: oral
Route: multiple
Dose: 50 mg/m2, 2 times / week
Sources:
unhealthy, 63 years (range: 31-80 years)
n = 73
Health Status: unhealthy
Age Group: 63 years (range: 31-80 years)
Sex: M+F
Population Size: 73
Sources:
Fatigue grade 3, 11%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Diarrhea grade 3, 3%
Disc. AE
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Pyrexia grade 3, 4%
Disc. AE
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Nausea grade 3, 6%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Hyponatraemia grade 3, 8%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Anaemia grade 4, 1%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Dyspnoea grade 4, 1%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Thrombocytopenia grade 4, 15%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Neutropenia grade 4, 9%
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Acute respiratory distress syndrome grade 5, 1 patient
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Cerebrovascular accident grade 5, 1 patient
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Sepsis grade 5, 3 patients
60 mg 2 times / week multiple, oral
Dose: 60 mg, 2 times / week
Route: oral
Route: multiple
Dose: 60 mg, 2 times / week
Sources:
unhealthy, 67 years (range: 35–87 years)
n = 127
Health Status: unhealthy
Age Group: 67 years (range: 35–87 years)
Sex: M+F
Population Size: 127
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
yes [IC50 6.2 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
yes
yes
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
2013 Jan
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
2014 Jan
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.
2016 Dec 7
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
2016 May 1
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.
2017 Aug
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
2017 Aug 29
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
2017 Jan 31
Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
2017 Jun 13
Patents

Sample Use Guides

60 mg (∼35 mg/m2) given twice weekly in a 4-week cycle based on the totality of safety and efficacy data.
Route of Administration: Oral
To determine whether inhibition of cell growth was due to an alteration in the cell cycle, we analyzed cell cycle distribution of Anaplastic thyroid carcinoma (ATC) cells either exposed to various concentrations (0–1000 nM, 48 h) of selinexor or XPO1 was silenced by transfection with XPO1 shRNA. XPO1 inhibition significantly increased G1 phase and decreased the S and G2/M phases in ATC cells. Of note, selinexor treatment resulted in cell cycle arrest in a dose-dependent manner. Further, was observed that selinexor altered the expression of its known cargo proteins (e.g., p53, p27 and p21), as well as indirect targets including cyclin B1, cyclin D1 in the ATC cell lines. Selinexor treatment (1000 nM, 24 h) also increased cleaved PARP, cleaved caspase-9 and cleaved caspase-3 in ATC cells. Cleavage of PARP [poly (ADP-ribose) polymerase is one of the hallmarks of apoptosis and caspase activation. This was associated with a decrease in the protein levels of anti-apoptotic proteins such as MCL1 and C-Myc. Moreover, was evaluated the dose-dependent effect of selinexor on the protein expression of a few important genes in CAL62 cells
Name Type Language
SELINEXOR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
SELINEXOR [USAN]
Common Name English
SELINEXOR [WHO-DD]
Common Name English
(Z)-3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-N'-(PYRAZIN-2-YL)ACRYLOHYDRAZIDE
Systematic Name English
SELINEXOR [INN]
Common Name English
KPT-330
Code English
2-PROPENOIC ACID, 3-(3-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1,2,4-TRIAZOL-1-YL)-, 2-(2-PYRAZINYL)HYDRAZIDE, (2Z)-
Systematic Name English
XPOVIO
Brand Name English
SELINEXOR [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 436414
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
NCI_THESAURUS C274
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
FDA ORPHAN DRUG 527816
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
EU-Orphan Drug EU/3/14/1355
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
FDA ORPHAN DRUG 432414
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
FDA ORPHAN DRUG 459014
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
Code System Code Type Description
FDA UNII
31TZ62FO8F
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
EVMPD
SUB177942
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
CAS
1393477-72-9
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
DRUG BANK
DB11942
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
PUBCHEM
71481097
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
NCI_THESAURUS
C102546
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
LACTMED
Selinexor
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
DRUG CENTRAL
5330
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
RXCUI
2178390
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
INN
9872
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545185
Created by admin on Sat Jun 26 14:22:26 UTC 2021 , Edited by admin on Sat Jun 26 14:22:26 UTC 2021
PRIMARY